To promote the production of its best-selling cancer drug, Keytruda , to the , U. S.  , and speed up the development of new drugs to market, Merk, the , the New Jersey-based pharmaceutical giant, is investing$ 1 billion in a new , Delaware , shop.
Keytruda is now produced in Ireland and the United States by deal manufacturers. Donald Trump, the president, has complained about Ireland acting as a low-cost medicine stock and tax shelter at the expense of U.S. workers, tax collectors, and other parties.
The new Merck , Wilmington , complex will be the” cornerstone of our biotech future,” according to Robert W. Davis, chief executive at a breakthrough on Tuesday on the former DuPont Co. substance and business campus. It will be” the future , U. S.  , house for producing Keytruda for , U. S.  , people,” according to the company’s website.
By the time building is finished in five years and there are likely thousands more long-term jobs in drug development, Davis said Merck , which may employ robotics and artificial intelligence software.
Sanat Chattopadhyay, chairman of the company’s manufacturing sector, stated in a statement that” this is a significantly new age in substance development.” We will be able to accelerate up patient access by producing bio-based and complicated solutions in the United States for the U.S. market, according to the statement.
Representatives from Merck  said the page was chosen over rival sites in , Pennsylvania,  , Maryland,  , North Carolina,  , Massachusetts, and other state where , Merck , has services. Officials in Delaware and the United States earlier this year approved grants of up to$ 30 million for the project to help attract Merck.
With 14, 700 employees spread across its , Upper Gwynedd Township , practices, West Point producing plants, and , Spring House , study labs, all located in , Montgomery County, and various place sites, the company is one of the larger employers in the , Philadelphia , place.
The original DuPont Co. laboratories are being planned by Merck . Study and manufacturing facility for Chestnut Run at , 984 Centre Rd. By 2028, increase production and offices, and include manufacturing and workplaces by 2030.
Delaware’s gain is not Pennsylvania’s loss, according to Mike Wojewodka, leader of MRA Group, a developer that has also constructed biotechnology centers at former professional sites in , Philadelphia , and , Montgomery County. He claimed that no matter where the facilities are, both states are among those who are competing for bioscience facilities and benefit from significant regional employers expanding.
Both governors spoke at the breakthrough. People from Merck’s office in Rahway, New Jersey, and Matt Meyer, New Castle County, Executive andnbsp, Marcus Henry, smiled as they urged employees to relocate to Delaware, where property taxes are lower than in the Garden State.
The , Wilmington , place will be home to the company’s drones, artificial intelligence software, and other innovative technologies.
One of its objectives is to develop abdominal drug delivery ( injection straight into fatty tissue below the skin ) for Keytruda, create antibody-drug compounds that combine biologically refractory cell with chemotherapy drugs, and streamline production to deliver new products to clients more quickly than older species, according Chattopadhyay said.
In 2021, MRA, with initial funding from Fulton Bank, sold and spun off a number of business units as DuPont CEO Edward Breen, who had previously held the position, for$ 40 million. More than 30 000 people lived in Delaware and the state’s economy when DuPont and its chemical and materials businesses reached their peak in the 1970s. It currently has about 2,500 employees.
The developer is overseeing the site’s pollution remediation and has leveled old buildings.
Along with other amenities, the new , Merck , factory is under construction, as is a rising , Marriott Residence Inn, and a childcare facility for employees ‘ families.
DuPont, a chemical producer, Celanese, a former DuPont business, and Solenis and Prelude, two other Delaware-based biotech companies, are other tenants at the complex. Prelude  is a spinoff of another , Delaware-based biotech company, publicly traded, and Wilmington-based Incyte, the largest drug company established in the , Philadelphia , area since the 1990s.
The new facility is being built at a time when the investment boom in the late 2010s caused the country’s cities, Philadelphia, and area to decline in biotech and manufacturing.
Other biotech projects by MRA include those in Spring House, near Merck’s labs, University City near the University of Pennsylvania, near Veterans ‘ Administration hospitals, and Pennovation, Penn’s engineering and business center at the former DuPont paint factory in South Philadelphia.
Merck , one of its smaller , Pennsylvania , facilities, announced plans to close its Cherokee plant in , Northumberland County, idling 163 workers in March.
___
The Philadelphia Inquirer, LLC, 2025.
Tribune Content Agency, LLC distributed.
